ACTRN12622001380785招募中2 期
Ambroxol therapy for ALS trial: a double-blind,randomised, placebo-controlled Phase 2 clinical trial of ambroxol forALS
The Florey Institute of Neuroscience and Mental Health (part of the University of Melbourne)0 个研究点目标入组 50 人开始时间: 2022年10月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •1. Must have given written informed consent before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events.
- •2. ALS as diagnosed according to the recently proposed Gold Coast diagnostic criteria.
- •3. First symptom of ALS less than or equal to 18 months prior to screening. The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.
- •4. Forced vital capacity (FVC) greater than or equal to 60% of predicted value as adjusted for gender, height and age at the Screening Visit.
- •5. Male or female patients aged 18 years or greater (inclusive) and less than 85 years at the time of ALS diagnosis.
- •6. Able to swallow liquid.
- •7. Able to perform reproducible pulmonary function tests
- •8. Female patients must be post-menopausal or sterilized or must not be breastfeeding, have no intention to become pregnant during the study, and use acceptable methods of contraception or abstain from intercourse.
- •9. Male patients who have not had a vasectomy and confirmed zero sperm count must agree after receiving the first dose of study drug either to use acceptable methods of contraception or abstain from intercourse.
- •10. If on riluzole, stable dosing for 30-days prior to screening.
- •11. Pre-study ALSFRS-R progression between disease onset and screening of greater than or equal to 0.5 points/month (calculated by ALSFRS-R total score decline from 48 divided by the months since onset of ALS symptoms).
排除标准
- •1. Use of non-invasive ventilation (NIV) support for ALS only or gastrostomy tube at time of screening.
- •2. Exposure to investigational drug within 12-weeks prior to screening.
- •3. At screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or data.
- •4. Patient with a history of significant other major medical conditions based on the Investigator’s judgment.
- •5. Based on the investigator’s judgment, patients who may have difficulty complying with the protocol and/or any study procedures.
- •6. Any person who is an employee or an Investigator or Sponsor, or an immediate relative of an Investigator.
研究者
相似试验
招募中
2 期
A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALSAmyotrophic Lateral SclerosisNCT05959850The Florey Institute of Neuroscience and Mental Health50
已完成
3 期
Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore ThroatPharyngitisNCT00525044Boehringer Ingelheim249
尚未招募
1 期
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body DementiaLewy Body DiseaseNCT04405596Lawson Health Research Institute15
已完成
1 期
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male VolunteersHealthyNCT02194283Boehringer Ingelheim34
已完成
2 期
Ambroxol as a Disease-modifying Treatment in GBA-PDGBA Gene MutationParkinson DiseaseNCT05287503Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta65